Literature DB >> 26095299

CXCR4 3'UTR functions as a ceRNA in promoting metastasis, proliferation and survival of MCF-7 cells by regulating miR-146a activity.

Tianjing Zheng1, Jinjiang Chou1, Feng Zhang1, Yu Liu2, Haiwei Ni3, Xiaoman Li1, Lufeng Zheng1, Tingting Tang1, Liang Jin2, Tao Xi4.   

Abstract

CXCR4 is the most common chemokine receptor expressed on tumor cells, and it is closely correlated with cancer cell stemness. This study was carried out to explore whether CXCR4 could function as a competitive endogenous RNA to promote metastasis, proliferation and survival in MCF-7 breast cancer cells. We validated that CXCR4, together with TRAF6 and EGFR, was directly targeted by miR-146a in MCF-7 cells. Overexpression of CXCR4 3'UTR inhibited the activity of miR-146a, thus elevating the expression of CXCR4, TRAF6 and EGFR. These oncoproteins further activated NF-κB pathway and promoted the proliferation, migration, invasion and anti-apoptotic activity of MCF-7 cells. Collectively, our study provided new insights into the function of CXCR4 in breast cancer: it promotes tumor progression as both a protein-coding gene and a non-coding RNA, complicating the mechanism by which oncogenes promote tumor progression.
Copyright © 2015 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Breast cancer; CXCR4 3′UTR; Competitive endogenous RNA; EGFR; TRAF6; miR-146a

Mesh:

Substances:

Year:  2015        PMID: 26095299     DOI: 10.1016/j.ejcb.2015.05.010

Source DB:  PubMed          Journal:  Eur J Cell Biol        ISSN: 0171-9335            Impact factor:   4.492


  14 in total

Review 1.  Endogenous microRNA sponges: evidence and controversy.

Authors:  Daniel W Thomson; Marcel E Dinger
Journal:  Nat Rev Genet       Date:  2016-04-04       Impact factor: 53.242

Review 2.  Regulation of epithelial-mesenchymal transition through microRNAs: clinical and biological significance of microRNAs in breast cancer.

Authors:  Fu Peng; Liang Xiong; Hailin Tang; Cheng Peng; Jianping Chen
Journal:  Tumour Biol       Date:  2016-09-19

3.  Upregulating miR-146a by physcion reverses multidrug resistance in human chronic myelogenous leukemia K562/ADM cells.

Authors:  Wenjun Liu; Juan He; Yiling Yang; Qulian Guo; Fei Gao
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

4.  MicroRNA-146a inhibits cell migration and invasion by targeting RhoA in breast cancer.

Authors:  Qin Liu; Wei Wang; Xiongfa Yang; Dongxiao Zhao; Fangqiong Li; Hai Wang
Journal:  Oncol Rep       Date:  2016-05-06       Impact factor: 3.906

5.  STARD13-correlated ceRNA network inhibits EMT and metastasis of breast cancer.

Authors:  Xiaoman Li; Lufeng Zheng; Feng Zhang; Jinhang Hu; Jinjiang Chou; Yu Liu; Yingying Xing; Tao Xi
Journal:  Oncotarget       Date:  2016-04-26

6.  Co-expression analysis revealed PTCH1-3'UTR promoted cell migration and invasion by activating miR-101-3p/SLC39A6 axis in non-small cell lung cancer: implicating the novel function of PTCH1.

Authors:  Xuechao Wan; Zhe Kong; Kaili Chu; Chuanyou Yi; Jian Hu; Rui Qin; Chen Zhao; Fangqiu Fu; Hai Wu; Yao Li; Yan Huang
Journal:  Oncotarget       Date:  2017-12-13

7.  MiR-146a-5p inhibits cell proliferation and cell cycle progression in NSCLC cell lines by targeting CCND1 and CCND2.

Authors:  Yan-Li Li; Ju Wang; Cai-Yan Zhang; Yu-Qing Shen; Hui-Min Wang; Lei Ding; Yu-Chen Gu; Jia-Tao Lou; Xin-Tai Zhao; Zhong-Liang Ma; You-Xin Jin
Journal:  Oncotarget       Date:  2016-09-13

8.  Registered report: Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs.

Authors:  Mitch Phelps; Chris Coss; Hongyan Wang; Matthew Cook
Journal:  Elife       Date:  2016-03-01       Impact factor: 8.140

9.  Effect of miR‑146a‑5p on tumor growth in NSCLC using chick chorioallantoic membrane assay and bioinformatics investigation.

Authors:  Wen-Ting Huang; Wei-Luan Cen; Rong-Quan He; You Xie; Yu Zhang; Ping Li; Ting-Qing Gan; Gang Chen; Xiao-Hua Hu
Journal:  Mol Med Rep       Date:  2017-10-04       Impact factor: 2.952

10.  miRNA-mediated 'tug-of-war' model reveals ceRNA propensity of genes in cancers.

Authors:  Arpit Chandan Swain; Bibekanand Mallick
Journal:  Mol Oncol       Date:  2018-04-17       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.